EFFICACY DATA

BRIUMVI is where efficacy meets efficiency for patients with relapsing MS

Down arrow iconSignificant relapse reduction (primary endpoint)

Down arrow iconNear-complete suppression of lesions

Down arrow iconDescriptive analyses of CDP and CDI

Down arrow iconPooled post hoc analyses of NEDA

BRIUMVI was evaluated in 2 identical phase 3 global randomized studies: ULTIMATE I and II

The first and only anti-CD20 to achieve an ARR <0.1 in 2 phase 3 clinical trials1,2,a

BRIUMVI significantly reduced ARR vs teriflunomide at 96 weeks1,2

BRIUMVI® (ublituximab-xiiy) Annualized Relapse Rate (ARR) Chart

Less than 1 relapse for every 13 patient-years with BRIUMVI in ULTIMATE I study3

Less than 1 relapse for every 11 patient-years with BRIUMVI in ULTIMATE II study3

Based on mITT population. The mITT population consists of all subjects in the ITT population who received at least 1 dose of study medication and had at least 1 baseline and postbaseline efficacy assessment.
aARR for BRIUMVI observed in the ULTIMATE I and II phase 3 trials. Cross-trial comparisons are not appropriate given variation in patient populations enrolled across different trials.

More patients stayed relapse-free with BRIUMVI across the 2 clinical trials4

BRIUMVI® (ublituximab-xiiy) Clinical Trials patient relapse percentage results vs. Teriflunomide

Post hoc analysis. Based on Kaplan-Meier estimates and mITT population.

A portrait of Alex, a person with RMS taking BRIUMVI® (ublituximab-xiiy)

“My doctor says I am doing really well on BRIUMVI, I haven’t had any relapses or any new or enlarging lesions.”

– Alex K. (clinical trial patient) has taken BRIUMVI since 2017

Individual results may vary

BRIUMVI showed near-complete suppression of lesions compared
with teriflunomide1,2

T1 Gd+ lesions were suppressed by 97% compared with teriflunomide1,2

BRIUMVI® (ublituximab-xiiy) T1 Gd+ lesions at Week 96 Chart

Based on MRI-mITT population (mITT patients who have baseline and postbaseline MRI).

T2 lesions were suppressed by 92% in ULTIMATE I and 90% in ULTIMATE II compared with teriflunomide1,2

BRIUMVI® (ublituximab-xiiy) New or enlarging T2 lesions at Week 96 Chart

Based on MRI-mITT population (mITT patients who have baseline and postbaseline MRI).

ULTIMATE I and II Trials Evaluated the Progression of Disability in Patients at 12 and 24 Weeks1,2

Descriptive analysis

BRIUMVI® (ublituximab-xiiy) Confirmed disability progression (CDP) Chart

Based on Kaplan-Meier estimates and mITT population.

  • CDP at 12 weeks between the 2 treatment groups did not reach statistical significance
  • CDP at 24 weeks was not formally tested for significance
  • Disease progression was measured by EDSS and defined as an increase of ≥1.0 point from the baseline EDSS score if the baseline score was ≤5.5, or an increase of ≥0.5 points if the baseline score was >5.5

ULTIMATE I and II trials evaluated improvement of disability in patients2

Descriptive analysis

BRIUMVI® (ublituximab-xiiy) Confirmed disability improvement (CDI) Chart

Based on Kaplan-Meier estimates and mITT population.

  • CDI at 12 and 24 weeks was not formally tested for significance
  • Disability improvement was defined as a reduction of ≥1.0 point from the baseline EDSS score, or a reduction of ≥0.5 points if the baseline EDSS score was >5.5

Pooled post hoc analysis: NEDA (No Evidence of Disease Activity) weeks 0-965

About NEDA-35

NEDA-3 is a composite assessment defined as patients with

  • No confirmed relapses
  • No 12-week CDP
  • No lesion activity detected via MRI

Pooled post hoc analysis

12%

of patients receiving
Teriflunomide

(n=524)

NEDA-3
(weeks 0-96)

VS icon

45%

of patients receiving
BRIUMVI

(n=520)

Percentage of patients treated with BRIUMVI achieving individual component measures of NEDA-35

 

86.5% No confirmed relapses

94.0% No Gd+ T1 lesions

55.2% No new/enlarging T2 lesions

94.6% No 12-week CDP

Limitations of NEDA in ULTIMATE I and ULTIMATE II:
The predefined secondary endpoint was not statistically significant, and it was considered nonconfirmatory because it fell below the break in the statistical hierarchy at time to CDP for at least 12 weeks during the 96-week treatment period.  No conclusions can be drawn.

Pooled post hoc analysis: rebaselined NEDA (No Evidence of Disease Activity) weeks 24-965

NEDA analyses are often rebaselined to a later time point post-treatment initiation to better reflect the steady state of DMT’s impact on disease and to minimize any impact of pretreatment disease activity.6

BRIUMVI® (ublituximab-xiiy) Rebaseline Chart

Pooled post hoc analysis

23%

of patients receiving
Teriflunomide

(n=511)

Rebaselined NEDA-3
(weeks 24-96)

82%

of patients receiving
BRIUMVI

(n=509)

Percentage of patients treated with BRIUMVI achieving individual component measures of NEDA-3 (rebaselined)5

 

88.6% No confirmed relapses

99.4% No Gd+ T1 lesions

96.9% No new/enlarging T2 lesions

95.1% No 12-week CDP

Limitations of NEDA in ULTIMATE I and ULTIMATE II:
The predefined secondary endpoint was not statistically significant, and it was considered nonconfirmatory because it fell below the break in the statistical hierarchy at time to CDP for at least 12 weeks during the 96-week treatment period.  No conclusions can be drawn.

Explore the safety profile
of BRIUMVI

See Safety

Find information on BRIUMVI dosing
and administration

See Dosing & Administration

References: 1. BRIUMVI. Prescribing information. TG Therapeutics Inc; 2022. 2. Steinman L, Fox E, Hartung H-P, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704-714. doi:10.1056/NEJMoa2201904. 3. Data on file. TG Therapeutics Inc. 4. Steinman L, Fox EJ, Hartung H-P, et al. Relapse rate and time to first relapse were improved with ublituximab vs teriflunomide in the phase 3 ULTIMATE I and ULTIMATE II studies in patients with relapsing multiple sclerosis (RMS). Presented at: 2022 American Academy of Neurology (AAN) Annual Meeting; April 2-7, 24-26, 2022; Seattle, WA. 5. Alvarez E, Steinman L, Fox EJ, et al. Ublituximab treatment is associated with a significant proportion of patients achieving no evidence of disease activity (NEDA): results from the ULTIMATE I and ULTIMATE II phase 3 studies of ublituximab vs teriflunomide in relapsing multiple sclerosis (RMS). Presented at: 2022 American Academy of Neurology (AAN) Annual Meeting; April 2-7, 24-26, 2022; Seattle, WA. 6. Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord. 2015;4(4):329-333. doi:10.1016/j.msard.2015.04.006.

Have questions?

Call 1-833-BRIUMVI (1-833-274-8684) to speak with a BRIUMVI Patient Support
Case Manager (Mon-Fri, 8 AM to 8 PM ET)

Sign up for more information and request a
TG Therapeutics Representative

Sign Up

Indication and Important Safety Information

IMPORTANT SAFETY INFORMATION

Contraindication: BRIUMVI is contraindicated in patients with:

  • Active HBV infection
  • A history of life-threatening infusion reaction to BRIUMVI

WARNINGS AND PRECAUTIONS

Infusion Reactions:

BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction. In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was 48%, with the highest incidence within 24 hours of the first infusion. 0.6% of BRIUMVI-treated patients experienced infusion reactions that were serious, some requiring hospitalization.

Observe treated patients for infusion reactions during the infusion and for at least one hour after the completion of the first two infusions unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion. Administer the recommended pre-medication to reduce the frequency and severity of infusion reactions. If life-threatening, stop the infusion immediately, permanently discontinue BRIUMVI, and administer appropriate supportive treatment. Less severe infusion reactions may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.

Infections: Serious, life-threatening or fatal, bacterial and viral infections have been reported in BRIUMVI-treated patients. In MS clinical trials, the overall rate of infections in BRIUMVI-treated patients was 56% compared to 54% in teriflunomide-treated patients. The rate of serious infections was 5% compared to 3% respectively. There were 3 infection-related deaths in BRIUMVI-treated patients. The most common infections in BRIUMVI-treated patients included upper respiratory tract infection (45%) and urinary tract infection (10%). Delay BRIUMVI administration in patients with an active infection until the infection is resolved.

Consider the potential for increased immunosuppressive effects when initiating BRIUMVI after immunosuppressive therapy or initiating an immunosuppressive therapy after BRIUMVI.

Hepatitis B Virus (HBV) Reactivation: HBV reactivation occurred in an MS patient treated with BRIUMVI in clinical trials. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with BRIUMVI. Do not start treatment with BRIUMVI in patients with active HBV confirmed by positive results for HBsAg and anti-HB tests. For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult a liver disease expert before starting and during treatment.

Progressive Multifocal Leukoencephalopathy (PML): Although no cases of PML have occurred in BRIUMVI-treated MS patients, JCV infection resulting in PML has been observed in patients treated with other anti-CD20 antibodies and other MS therapies.

If PML is suspected, withhold BRIUMVI and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.

MRI findings may be apparent before clinical signs or symptoms; monitoring for signs consistent with PML may be useful. Further investigate suspicious findings to allow for an early diagnosis of PML, if present. Following discontinuation of another MS medication associated with PML, lower PML-related mortality and morbidity have been reported in patients who were initially asymptomatic at diagnosis compared to patients who had characteristic clinical signs and symptoms at diagnosis.

If PML is confirmed, treatment with BRIUMVI should be discontinued.

Vaccinations: Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines at least 4 weeks and, whenever possible at least 2 weeks prior to initiation of BRIUMVI for non-live vaccines. BRIUMVI may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines during or following administration of BRIUMVI has not been studied. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion.

Vaccination of Infants Born to Mothers Treated with BRIUMVI During Pregnancy: In infants of mothers exposed to BRIUMVI during pregnancy, assess B-cell counts prior to administration of live or live-attenuated vaccines as measured by CD19+ B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines. Inactivated or non-live vaccines may be administered prior to B-cell recovery. Assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to determine whether a protective immune response was mounted.

Fetal Risk: Based on data from animal studies, BRIUMVI may cause fetal harm when administered to a pregnant woman. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. A pregnancy test is recommended in females of reproductive potential prior to each infusion. Advise females of reproductive potential to use effective contraception during BRIUMVI treatment and for 6 months after the last dose.

Reduction in Immunoglobulins: As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Decrease in immunoglobulin M (IgM) was reported in 0.6% of BRIUMVI-treated patients compared to none of the patients treated with teriflunomide in RMS clinical trials. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy until B-cell repletion. Consider discontinuing BRIUMVI therapy if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.

Most Common Adverse Reactions: The most common adverse reactions in RMS trials (incidence of at least 10%) were infusion reactions and upper respiratory tract infections.

INDICATION

BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Privacy Policy | Terms of Use | Contact Us | About TG Therapeutics

Indication and Important Safety Information

INDICATION: BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

IMPORTANT SAFETY INFORMATION: Contraindication: BRIUMVI is contraindicated in patients with:

- Active HBV infection
- A history of life-threatening infusion reaction to BRIUMVI

  • fever
  • chills
  • headache
  • flu-like symptoms
  • fast heartbeat
  • hives
  • itchy skin
  • dizziness

  • feeling faint
  • welling of tongue or throat
  • trouble breathing
  • wheezing
  • nausea
  • abdominal pain
  • throat irritation
  • redness of the face or skin

 

These infusion reactions can happen over 24 hours after your infusion. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion. If you get an infusion reaction, your healthcare provider may need to stop or slow down the rate of your infusion.

  • Infection:
    • Infections are a common side effect, and upper respiratory tract infections are one of the most common side effects of BRIUMVI. BRIUMVI increases your risk of getting infections caused by bacteria or viruses that may be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, a cough that does not go away, or painful urination. Your healthcare provider should delay your treatment with BRIUMVI until your infection is gone.
    • Hepatitis B virus (HBV) reactivation: Before starting treatment with BRIUMVI, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with BRIUMVI. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving BRIUMVI.
    • Weakened immune system: BRIUMVI taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
    • Progressive Multifocal Leukoencephalopathy (PML): PML may happen with BRIUMVI. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms. These symptoms may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory which may lead to confusion, and personality changes.
  • Low immunoglobulins: BRIUMVI may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.


Before receiving BRIUMVI, tell your healthcare provider about all of your medical conditions, including if you:

  • have or think you have an infection.
  • take or plan to take medicines that affect your immune system. These medicines may increase your risk of getting an infection.
  • have ever had hepatitis B or are a carrier of the hepatitis B virus.
  • have had a recent vaccination or are scheduled to receive any vaccinations.
    • You should receive any required ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before you start treatment with BRIUMVI. You should not receive ‘live’ or ‘live-attenuated’ vaccines while you are being treated with BRIUMVI and until your healthcare provider tells you that your immune system is no longer weakened.
    • When possible, you should receive any ‘non-live’ vaccines at least 2 weeks before you start treatment with BRIUMVI. If you would like to receive any non-live vaccines while you are being treated with BRIUMVI, talk to your healthcare provider.
    • If you have a baby and you received BRIUMVI during your pregnancy, it is important to tell your baby’s healthcare provider about receiving BRIUMVI so they can decide when your baby should be vaccinated.
  • are pregnant, think that you might be pregnant, or plan to become pregnant. BRIUMVI may harm your unborn baby. You should use birth control (contraception) during treatment with BRIUMVI and for at least 6 months after your last infusion of BRIUMVI. Talk with your healthcare provider about what birth control method is right for you during this time.
  • are breastfeeding or plan to breastfeed. It is not known if BRIUMVI passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take BRIUMVI.


Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of BRIUMVI?

The most common side effects of BRIUMVI include:

  • Infusion reactions, upper and lower respiratory tract infections, herpes infections, extremity pain, insomnia, and fatigue.


These are not all the possible side effects of BRIUMVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to TG Therapeutics at 1-877-TGTXINC (1-877-848-9462).

For more important information, go to www.briumvi.com or call 1-833-BRIUMVI (1-833-274-8684).